BIO-RAD LABORATORIES, INC.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Income (Loss)

(In millions, except number of shares, which are reflected in thousands, and per share data)

(Unaudited)

Three Months Ended · Six Months Ended
	June 30,		June 30,
	2026	2025	2026	2025
Net sales	$651.0	$651.6	$1,243.1	$1,237.0
Cost of goods sold	305.2	306.3	587.9	585.7
Gross profit	345.8	345.3	655.2	651.3
Selling, general and administrative expense	212.0	207.7	424.4	416.5
Research and development expense	61.2	60.5	124.1	134.0
Income from operations	72.6	77.1	106.7	100.8
Interest expense	12.1	12.6	24.4	24.6
Foreign currency exchange (gains) losses, net	(0.2)	1.1	(2.6)	(1.6)
(Gains) losses from change in fair market value of equity securities and loan receivable	(458.0)	(334.4)	280.2	(366.2)
Other income, net	(23.4)	(16.2)	(47.6)	(53.4)
Income (loss) before income taxes	542.1	414.0	(147.7)	497.4
Provision for income taxes	(170.7)	(96.2)	(8.0)	(115.6)
Net income (loss)	$371.4	$317.8	$(155.7)	$381.8
Basic earnings (loss) per share:
Net income (loss) per basic share	$13.89	$11.67	$(5.80)	$13.84
Weighted average common shares - basic	26,746	27,226	26,852	27,581
Diluted earnings (loss) per share:
Net income (loss) per diluted share	$13.85	$11.67	$(5.80)	$13.84
Weighted average common shares - diluted	26,814	27,228	26,852	27,589

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.